Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CLR003
MIFTS: 57

Clear Cell Adenocarcinoma

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Clear Cell Adenocarcinoma

About this section

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma 12 15 17
Mesonephroma 12 45 74
Water-Clear Cell Adenocarcinoma 12 74
Adenocarcinoma, Clear Cell 45 74
Mesonephroid Clear Cell Carcinoma 12
Water-Clear Cell Carcinoma 12
Adenocarcinoma Clear Cell 56
Mesonephroma, Malignant 12
Malignant Mesonephroma 12
Wolffian Duct Neoplasm 12
Mesonephric Tumor 74

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Clear Cell Adenocarcinoma

About this section
Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is MUC16 (Mucin 16, Cell Surface Associated), and among its related pathways/superpathways are Gastric cancer and Endometrial cancer. The drugs Carboplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Wikipedia : 77 Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Sources

Related Diseases for Clear Cell Adenocarcinoma

About this section

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 urethra clear cell adenocarcinoma 34.2 AMACR KLK3 SMAD4
2 ovarian clear cell adenocarcinoma 33.9 ARID1A HNF1B SMAD3
3 clear cell adenofibroma 30.1 ARID1A KRT7
4 transitional cell carcinoma 30.0 KRT20 KRT7 TP53
5 vulva adenocarcinoma 29.9 KRT20 KRT7
6 urethral diverticulum 29.9 AMACR KLK3 KRT7 PAX8
7 endosalpingiosis 29.8 KRT7 PAX8
8 gastric adenocarcinoma 29.5 KRT20 KRT7 SMAD4 TP53
9 ovary adenocarcinoma 29.5 ARID1A HNF1B KRT7 TP53
10 nephrogenic adenoma 29.3 AMACR KLK3 KRT7 PAX2 PAX8
11 ovarian cancer 1 29.1 ARID1A HNF1B KRT7 PAX8 TP53
12 clear cell renal cell carcinoma 29.0 KRT7 PAX2 PAX8 TP53
13 endocervical adenocarcinoma 29.0 KRT20 KRT7 PAX2 PAX8 TP53
14 renal cell carcinoma, nonpapillary 28.2 AMACR HNF1B KRT20 KRT7 PAX2 PAX8
15 bladder clear cell adenocarcinoma 12.5
16 bile duct clear cell adenocarcinoma 12.5
17 clear cell adenocarcinoma of the ovary 12.5
18 cervical clear cell adenocarcinoma 12.5
19 endometrial clear cell adenocarcinoma 12.5
20 fallopian tube clear cell adenocarcinoma 12.4
21 uterine ligament clear cell adenocarcinoma 12.3
22 ampulla of vater clear cell adenocarcinoma 12.3
23 bladder tubulo-cystic clear cell adenocarcinoma 12.3
24 bladder papillary clear cell adenocarcinoma 12.3
25 bladder diffuse clear cell adenocarcinoma 12.2
26 diethylstilbestrol syndrome 11.5
27 wolffian duct adenoma 11.4
28 epithelial-myoepithelial carcinoma 11.2
29 multilocular cystic renal neoplasm of low malignant potential 11.2
30 adenocarcinoma 11.2
31 endometriosis 10.6
32 submandibular gland cancer 10.4 KLK3 TP53
33 atrophy of prostate 10.4 KLK3 TP53
34 mutyh-associated polyposis 10.3 SMAD4 TP53
35 malignant spiradenoma 10.3 KRT7 TP53
36 spiradenoma 10.3 KRT7 TP53
37 vulvar intraepithelial neoplasia 10.3 KRT7 TP53
38 breast squamous cell carcinoma 10.3 PTHLH TP53
39 colloid adenoma 10.3 KRT20 TP53
40 oligomeganephronia 10.2 HNF1B PAX2
41 fibroepithelial basal cell carcinoma 10.2 KRT20 TP53
42 bladder carcinoma in situ 10.2 KRT7 TP53
43 cystic basal cell carcinoma 10.2 KRT20 KRT7
44 bladder papillary transitional cell neoplasm 10.2 KRT20 TP53
45 transverse colon cancer 10.2 KRT20 KRT7
46 urinary tract papillary transitional cell benign neoplasm 10.2 KRT20 TP53
47 appendix adenocarcinoma 10.2 KRT20 KRT7
48 malignant syringoma 10.2 KRT20 KRT7
49 urinary tract obstruction 10.2 KLK3 SMAD2 SMAD3
50 seminal vesicle tumor 10.2 KLK3 KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:



Diseases related to Clear Cell Adenocarcinoma
Sources

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

About this section

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.23 ARID1A HNF1B KLK3 KRT7 PAX8 SMAD3

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.18 ARID1A KRT7 PAX2 PAX8 PTHLH SMAD2
2 cardiovascular system MP:0005385 10.14 ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3
3 endocrine/exocrine gland MP:0005379 10.13 ARID1A HNF1B PAX2 PAX8 PTHLH SMAD2
4 homeostasis/metabolism MP:0005376 10.13 AMACR ARID1A HNF1B KRT7 PAX8 PTHLH
5 growth/size/body region MP:0005378 10.11 AMACR ARID1A HNF1B PAX8 PTHLH SMAD2
6 embryo MP:0005380 10.1 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
7 mortality/aging MP:0010768 10.07 AMACR ARID1A HNF1B PAX2 PAX8 PTHLH
8 craniofacial MP:0005382 10.05 ARID1A PAX8 PTHLH SMAD2 SMAD3 SMAD4
9 liver/biliary system MP:0005370 9.95 AMACR HNF1B PTHLH SMAD2 SMAD3 SMAD4
10 renal/urinary system MP:0005367 9.86 HNF1B KRT7 PAX2 PAX8 PTHLH SMAD3
11 neoplasm MP:0002006 9.8 ARID1A PTHLH SMAD2 SMAD3 SMAD4 TP53
12 reproductive system MP:0005389 9.76 ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3
13 skeleton MP:0005390 9.5 ARID1A PAX8 PTHLH SMAD2 SMAD3 SMAD4
14 vision/eye MP:0005391 9.17 ARID1A PAX2 PAX8 PTHLH SMAD2 SMAD3
Sources

Drugs & Therapeutics for Clear Cell Adenocarcinoma

About this section

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
6
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
7
Epirubicin Approved Phase 3 56420-45-2 41867
8
Gemcitabine Approved Phase 2, Phase 3,Phase 3 95058-81-4 60750
9
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
10
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
11
Olaparib Approved Phase 2, Phase 3,Phase 3 763113-22-0 23725625
12
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
13
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
14
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16
SB-649868 Experimental, Investigational Phase 2, Phase 3,Phase 3 110-16-7, 110-17-8 444972
17
Cediranib Investigational Phase 2, Phase 3,Phase 3 288383-20-0 9933475
18 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
19 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
23 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
24 Antimetabolites Phase 3,Phase 2,Phase 1
25 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunoglobulins Phase 3,Phase 2,Phase 1
27 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
30 Immunoglobulin G Phase 3,Phase 2,Phase 1
31 Antibodies Phase 3,Phase 2,Phase 1
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
34 Antimitotic Agents Phase 3,Phase 2,Phase 1
35 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
37 Mitogens Phase 3,Phase 2,Phase 1
38 Adjuvants, Immunologic Phase 3,Phase 1
39 Antiviral Agents Phase 3,Phase 2,Phase 1
40 Anti-Infective Agents Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
42 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
43 topoisomerase I inhibitors Phase 2, Phase 3
44 Micronutrients Phase 3,Not Applicable
45 Carotenoids Phase 3
46 Trace Elements Phase 3,Not Applicable
47 Hypoglycemic Agents Phase 2, Phase 3
48 taxane Phase 3,Not Applicable
49
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
50
Vinblastine Approved Phase 2 865-21-4 13342 241903

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
7 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
8 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
10 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
11 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
12 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
15 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
16 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
17 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
18 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
19 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
20 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
21 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Unknown status NCT02059265 Phase 2 Dasatinib
22 Immunochemotherapy for Metastatic Renal Cell Carcinoma Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
23 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
24 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
25 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
26 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
27 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
28 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
29 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
30 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
31 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
32 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
33 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
34 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
35 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
36 Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer Completed NCT00002562 Phase 2 paclitaxel
37 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
38 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
39 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
40 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
41 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
42 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
43 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
44 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
45 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
46 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
47 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
48 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
49 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
50 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Sources

Genetic Tests for Clear Cell Adenocarcinoma

About this section
Sources

Anatomical Context for Clear Cell Adenocarcinoma

About this section

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

42
Cervix, Ovary, Lymph Node, Colon, Lung, Kidney, Prostate
Sources

Publications for Clear Cell Adenocarcinoma

About this section

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 459)
# Title Authors Year
1
Clear cell adenocarcinoma of the lung: a population-based study. ( 30774428 )
2019
2
Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )
2018
3
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )
2018
4
Clear Cell Adenocarcinoma Arising from Endometriosis in the Groin: Wide Resection and Reconstruction with a Fascia Lata Tensor Muscle Skin Flap. ( 29805826 )
2018
5
Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review. ( 29977425 )
2018
6
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )
2018
7
Clear cell adenocarcinoma of female urethra: A case report. ( 29888186 )
2018
8
Clear cell adenocarcinoma of the urethra with inguinal lymph node metastases: A rare case report and review of literature. ( 29516944 )
2018
9
Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. ( 29719188 )
2018
10
Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. ( 29326971 )
2018
11
Primary clear cell adenocarcinoma of the pancreas: a case report and literature update. ( 30532559 )
2018
12
Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. ( 30202792 )
2018
13
Fairly rare clear cell adenocarcinoma mimicking liver cancer: a case report. ( 30117003 )
2018
14
Early stage clear cell adenocarcinoma of the colon examined in detail with image-enhanced endoscopy: a case report. ( 30062544 )
2018
15
Three cases of clear-cell adenocarcinoma arising from endometrioma during hormonal treatments. ( 29998468 )
2018
16
Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra. ( 28140610 )
2017
17
Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. ( 28689666 )
2017
18
Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. ( 28275694 )
2017
19
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )
2017
20
Clear cell adenocarcinoma of cervix in 1-year-old girl without in utero exposure to diethylstilbestrol: an uncommon tumour at an uncommon age and site. ( 28302659 )
2017
21
Clear Cell Adenocarcinoma of Female Urethra. ( 28892907 )
2017
22
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
23
Clear Cell Adenocarcinoma of the Female Urethra, Mimicking Cystocele. ( 28280687 )
2017
24
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
25
A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )
2016
26
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )
2016
27
Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )
2016
28
Clear Cell Adenocarcinoma of the Lung Mimicking Clear Cell Renal Cell Carcinoma. ( 29772138 )
2016
29
Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )
2016
30
Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )
2015
31
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )
2015
32
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )
2015
33
Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )
2015
34
Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )
2015
35
High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )
2015
36
Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )
2015
37
A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )
2015
38
Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )
2015
39
Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )
2015
40
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
41
Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )
2015
42
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
43
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
44
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
45
Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )
2014
46
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
47
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )
2014
48
Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )
2014
49
A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )
2014
50
Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )
2014
Sources

Variations for Clear Cell Adenocarcinoma

About this section

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 218693 7 116312458 116438439 Amplification MET Clear cell adenocarcinoma
2 266962 Y 174481503 174538309 Duplication AZF Clear cell adenocarcinoma
Sources

Expression for Clear Cell Adenocarcinoma

About this section
Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.
Sources

Pathways for Clear Cell Adenocarcinoma

About this section

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Gastric cancer 38
Show member pathways
 12.63 ARID1A SMAD2 SMAD3 SMAD4 TP53
2
Endometrial cancer 38
Show member pathways
 12.48 KLK3 PAX8 SMAD2 SMAD3 SMAD4 TP53
3
Human Embryonic Stem Cell Pluripotency 65
Show member pathways
 12.38 HNF1B SMAD2 SMAD3 SMAD4
4
Pathways in cancer 38
12.36 KLK3 PAX8 SMAD2 SMAD3 SMAD4 TP53
5
Human T-cell leukemia virus 1 infection 38
12.26 SMAD2 SMAD3 SMAD4 TP53
6
Cell cycle 38 1
12.25 SMAD2 SMAD3 SMAD4 TP53
7
Mesodermal Commitment Pathway 1
Show member pathways
 12.25 HNF1B PTHLH SMAD2 SMAD3 SMAD4
8
DNA Damage/Telomere Stress Induced Senescence 67
Show member pathways
 12.23 SMAD2 SMAD3 SMAD4 TP53
9
Wnt / Hedgehog / Notch 4
12.09 PAX2 SMAD2 SMAD3 SMAD4
10
Cellular senescence (KEGG) 38
12.07 SMAD2 SMAD3 TP53
11
Hippo signaling pathway 38
12.05 SMAD2 SMAD3 SMAD4
12
Integrated Breast Cancer Pathway 1
12.05 SMAD2 SMAD4 TP53
13
Signaling pathways regulating pluripotency of stem cells 38
12 SMAD2 SMAD3 SMAD4
14
FoxO signaling pathway 38
Show member pathways
 11.99 SMAD2 SMAD3 SMAD4
15
Apelin signaling pathway 38
11.99 SMAD2 SMAD3 SMAD4
16
Colorectal Cancer Metastasis 65
11.98 SMAD2 SMAD3 SMAD4 TP53
17
Th1 Differentiation Pathway 66
Show member pathways
 11.96 SMAD2 SMAD3 SMAD4
18
DNA Damage Response (only ATM dependent) 1
11.9 SMAD3 SMAD4 TP53
19
SMAD Signaling Network 65
11.88 SMAD2 SMAD3 SMAD4 TP53
20
Senescence and Autophagy in Cancer 1
11.86 SMAD3 SMAD4 TP53
21
TGF-beta Signaling Pathway (WikiPathways) 1
11.86 SMAD2 SMAD3 SMAD4 TP53
22
AGE-RAGE signaling pathway in diabetic complications 38
11.83 SMAD2 SMAD3 SMAD4
23
TGF-beta Signaling Pathways 66
11.81 SMAD2 SMAD3 SMAD4
24
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.79 SMAD2 SMAD3 SMAD4
25
Androgen receptor signaling pathway 1
11.78 KLK3 SMAD3 SMAD4
26
TGF-beta signaling pathway (KEGG) 38
11.76 SMAD2 SMAD3 SMAD4
27
Validated targets of C-MYC transcriptional activation 1
11.71 SMAD3 SMAD4 TP53
28
Regulation of nuclear SMAD2/3 signaling 1
11.69 SMAD2 SMAD3 SMAD4
29
Adherens junction 38
11.64 SMAD2 SMAD3 SMAD4
30
Development_TGF-beta receptor signaling 23
11.64 SMAD2 SMAD3 SMAD4
31
TGF-beta receptor signaling activates SMADs 67
Show member pathways
 11.62 SMAD2 SMAD3 SMAD4
32
IL-2 Gene Expression in Activated and Quiescent T-Cells 65
Show member pathways
 11.53 SMAD2 SMAD3 SMAD4
33
TGF-beta Receptor Signaling (WikiPathways) 1
11.52 SMAD2 SMAD3 SMAD4
34
Transcription_P53 signaling pathway 23
11.51 SMAD2 SMAD3 SMAD4 TP53
35
Hepatitis C and Hepatocellular Carcinoma 1
11.44 SMAD3 SMAD4 TP53
36
TGF-beta receptor signaling (Pathway Interaction Database) 1
11.43 SMAD2 SMAD3 SMAD4
37
Signaling by NODAL 67
Show member pathways
 11.41 SMAD2 SMAD3 SMAD4
38
Integrated Cancer Pathway 1
11.35 SMAD2 SMAD3 TP53
39
Extracellular vesicle-mediated signaling in recipient cells 1
11.06 SMAD2 SMAD3 SMAD4
40
NTHi-Induced Signaling 65
11.01 SMAD3 SMAD4
41
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
10.9 SMAD2 SMAD3 SMAD4
42
ID signaling pathway 1
10.87 PAX2 PAX8
43
Regulation of cytoplasmic and nuclear SMAD2/3 signaling 1
10.41 SMAD2 SMAD3 SMAD4
44
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.05 SMAD2 SMAD3 SMAD4
Sources

GO Terms for Clear Cell Adenocarcinoma

About this section

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.77 KLK3 PAX2 SMAD2 SMAD3 TP53
2 transcription factor complex GO:0005667 9.62 HNF1B SMAD2 SMAD3 SMAD4
3 nuclear chromatin GO:0000790 9.35 ARID1A SMAD2 SMAD3 SMAD4 TP53
4 activin responsive factor complex GO:0032444 9.26 SMAD2 SMAD4
5 heteromeric SMAD protein complex GO:0071144 9.16 SMAD2 SMAD3
6 SMAD protein complex GO:0071141 8.8 SMAD2 SMAD3 SMAD4
7 nucleus GO:0005634 10.14 ARID1A HNF1B KLK3 KRT7 PAX2 PAX8
8 nucleoplasm GO:0005654 10.03 ARID1A HNF1B PAX8 PTHLH SMAD2 SMAD3

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.95 SMAD2 SMAD3 SMAD4 TP53
2 negative regulation of cell growth GO:0030308 9.87 SMAD3 SMAD4 TP53
3 kidney development GO:0001822 9.86 HNF1B PAX8 SMAD4
4 anterior/posterior pattern specification GO:0009952 9.85 HNF1B SMAD2 SMAD4
5 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 SMAD2 SMAD3 SMAD4
6 SMAD protein signal transduction GO:0060395 9.81 SMAD2 SMAD3 SMAD4
7 positive regulation of epithelial to mesenchymal transition GO:0010718 9.76 SMAD2 SMAD3 SMAD4
8 branching involved in ureteric bud morphogenesis GO:0001658 9.75 PAX2 PAX8 SMAD4
9 thyroid gland development GO:0030878 9.71 PAX8 SMAD3
10 adrenal gland development GO:0030325 9.71 SMAD2 SMAD3
11 embryonic pattern specification GO:0009880 9.7 SMAD2 SMAD3
12 signal transduction involved in regulation of gene expression GO:0023019 9.7 SMAD2 SMAD3
13 osteoblast development GO:0002076 9.7 PTHLH SMAD3
14 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.7 PAX2 PAX8
15 activin receptor signaling pathway GO:0032924 9.69 SMAD2 SMAD3
16 urogenital system development GO:0001655 9.69 PAX2 PAX8
17 secondary palate development GO:0062009 9.68 SMAD2 SMAD4
18 mesonephros development GO:0001823 9.68 PAX2 PAX8
19 transcription by RNA polymerase II GO:0006366 9.67 PAX2 SMAD3
20 nodal signaling pathway GO:0038092 9.67 SMAD2 SMAD3
21 primary miRNA processing GO:0031053 9.66 SMAD2 SMAD3
22 embryonic foregut morphogenesis GO:0048617 9.66 SMAD2 SMAD3
23 pericardium development GO:0060039 9.65 SMAD2 SMAD3
24 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.65 PAX2 PAX8
25 mesonephric tubule development GO:0072164 9.64 HNF1B PAX8
26 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.64 PAX2 PAX8
27 metanephric epithelium development GO:0072207 9.63 PAX2 PAX8
28 developmental growth GO:0048589 9.63 SMAD2 SMAD3 SMAD4
29 gastrulation GO:0007369 9.62 ARID1A SMAD2 SMAD3 SMAD4
30 metanephric distal convoluted tubule development GO:0072221 9.61 PAX2 PAX8
31 metanephric nephron tubule formation GO:0072289 9.61 PAX2 PAX8
32 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.61 SMAD2 SMAD3 SMAD4
33 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.6 PAX2 PAX8
34 regulation of transforming growth factor beta2 production GO:0032909 9.59 SMAD3 SMAD4
35 SMAD protein complex assembly GO:0007183 9.58 SMAD2 SMAD3 SMAD4
36 nephric duct formation GO:0072179 9.57 HNF1B PAX2
37 endoderm development GO:0007492 9.56 HNF1B SMAD2 SMAD3 SMAD4
38 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.55 PAX2 PAX8
39 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.54 PAX2 PAX8
40 pronephros development GO:0048793 9.54 HNF1B PAX2 PAX8
41 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.52 PAX2 PAX8
42 paraxial mesoderm morphogenesis GO:0048340 9.51 SMAD2 SMAD3
43 positive regulation of metanephric DCT cell differentiation GO:2000594 9.49 PAX2 PAX8
44 pronephric field specification GO:0039003 9.48 PAX2 PAX8
45 regulation of binding GO:0051098 9.33 SMAD2 SMAD3 SMAD4
46 positive regulation of transcription, DNA-templated GO:0045893 9.23 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
47 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.13 HNF1B PAX2 PAX8
48 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 HNF1B PAX2 PAX8 SMAD2 SMAD3 SMAD4
49 negative regulation of transcription by RNA polymerase II GO:0000122 10.09 ARID1A HNF1B SMAD2 SMAD3 SMAD4 TP53
50 negative regulation of cell proliferation GO:0008285 10.02 PTHLH SMAD2 SMAD3 SMAD4 TP53

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.91 HNF1B PAX8 SMAD2 SMAD3 SMAD4 TP53
2 chromatin binding GO:0003682 9.86 SMAD2 SMAD3 SMAD4 TP53
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.86 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
4 transcription factor binding GO:0008134 9.85 PAX2 SMAD2 SMAD3 TP53
5 protein heterodimerization activity GO:0046982 9.85 HNF1B SMAD2 SMAD3 SMAD4 TP53
6 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 PAX8 SMAD2 SMAD3 SMAD4 TP53
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.62 SMAD2 SMAD3 SMAD4 TP53
8 enhancer binding GO:0035326 9.54 SMAD2 SMAD3
9 co-SMAD binding GO:0070410 9.52 SMAD2 SMAD3
10 I-SMAD binding GO:0070411 9.51 SMAD2 SMAD4
11 primary miRNA binding GO:0070878 9.49 SMAD2 SMAD3
12 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.37 SMAD2 SMAD3
13 R-SMAD binding GO:0070412 9.33 SMAD2 SMAD3 SMAD4
14 proximal promoter sequence-specific DNA binding GO:0000987 9.26 HNF1B PAX2 SMAD3 SMAD4
15 transcription regulatory region DNA binding GO:0044212 9.1 HNF1B PAX2 PAX8 SMAD3 SMAD4 TP53
16 DNA binding GO:0003677 10.08 ARID1A HNF1B PAX2 PAX8 SMAD2 SMAD3
Sources

Sources for Clear Cell Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....